Table 1.

Treatment status, health status, and demographic features of subject who did and did not receive KRAS testing as part of their clinical care for colorectal cancer. P-values are unadjusted, from chi-square tests.

Characteristic	Value	Tested	Not Tested	p-value	Characteristic	Value	Tested	Not Tested	p-value
Chemotherapy Regimens	0	13	171	<.0001	Race	White	306	520	<.0001
	1	28	146			Asian	42	52
	2	75	99			Black	37	90
	3	117	53			Pacific Is.	13	11
	4	80	49			Am. Indian	2	4
	>5	264	93			Other	10	31
						Unknown	15	55
Surgery1	No	105	351	<.0001	Ethnicity	Not Hispanic	319	592	0.0984
	Yes	322	410			Hispanic	27	45
Referral to Med. Oncology	No	5	166	<.0001	Gender	Male	222	379	0.1368
	Yes	407	610			Female	205	381
BMI Category	<20	17	61	<.0001	Household Income	< $40K	95	221	0.0024
	20-24	89	165			$40K - $59K	142	263
	25-29	122	182			$60K - $79K	90	141
	≥ 30	114	150			≥ $80K	63	107
Age at diagnosis, years	< 50	63	75	<.0001	% High School Education	< 50%	4	12	<.0001
	50-59	124	110			50-69%	36	63
	60-69	143	149			70-89%	197	383
	70-79	73	230			≥ 90%	166	260
	≥ 80	22	199
Charlson co-morbidity Index	0	291	356	<.0001	Year of Metastatic Diagnosis	2006	50	211	<.0001
	1	170	176			2007	123	228
	2	54	80			2008	179	194
	3	12	18			2009	93	110
	4	8	13		Medicare	No	274	581	<.0001
	≥ 5	2	8			Yes	150	183
Any EGFR inhibitor	No	262	674	<.0001	Organization	A	44	57	<.0001
	Yes	164	88			B	170	256
Survival Interval, years (if deceased)	0.5	28	438	0.0010		C	57	92
	0.5–1	36	94			D	66	127
	1 – 2	73	131			E	37	87
	≥ 2	241	147			F	18	44
Family History of Cancer	No	129	220	<.0001		G	37	96
	Yes	214	296		Cancer Stage	III	120	146	<.0001
	Unk	86	243			IV	313	609

¹Colectomy or hemicolectomy